

REC'D 08 APR 2005

WIPO

PCT

IB/04/04095

PA 1301263

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

March 30, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.


APPLICATION NUMBER: 60/529,142 ✓

FILING DATE: December 12, 2003 ✓

PRIORITY DOCUMENT

SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



P. SWAIN
Certifying Officer

BEST-AVAILABLE COPY

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No.

EV318329603US

INVENTOR(S)

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Benjamin	Sredni	Shachal 3 Kfar Saba Israel

☒ Additional inventors are being named on the 2 separately numbered sheets attached hereto

TITLE OF THE INVENTION (500 characters max)

METHOD OF TREATING FISH AND CRUSTACEANS WITH A TELLURIUM AND BASED IMMUNOMODULATOR

Direct all correspondence to:

CORRESPONDENCE ADDRESS

☐ Customer Number
OR
Type Customer Number here

Place Customer Number
Bar Code Label here

☒ Firm or Individual Name Hedman & Costigan, P.C.

Address James V. Costigan

Address 1185 Avenue of the Americas

City New York

State

New York

ZIP

10036-2646

Country USA

Telephone

212-302-8989

Fax

212-302-8998

ENCLOSED APPLICATION PARTS (check all that apply)

☒ Specification Number of Pages

15

☐ CD(s), Number

☒ Drawing(s) Number of Sheets

5

☐ Other (specify)

☐ Application Data Sheet. See 37 CFR 1.76

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT

☒ Applicant claims small entity status. See 37 CFR 1.27.

☒ A check or money order is enclosed to cover the filing fees

☒ The Commissioner is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number:

08-1540

FILING FEE
AMOUNT (\$)

\$80.00

☐ Payment by credit card. Form PTO-2038 is attached.

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number are:

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME James V. Costigan

TELEPHONE (212) 302-8989

Date 12/12/2003

REGISTRATION NO.
(if appropriate)
Docket Number:

25,669

116-044

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is used by the public to file (and by the PTO to process) a provisional application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the complete provisional application to the PTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Box Provisional Application, Assistant Commissioner for Patents, Washington, D.C. 20231.

PROVISIONAL APPLICATION COVER SHEET
Additional Page

PTO/SB/16 (02-01)

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Docket Number

116-044

INVENTOR(S)/APPLICANT(S)

Given Name (first and middle [if any])	Family or Surname	Residence (City and either State or Foreign Country)
Michael	Albeck	8 Harel Street 3 Ramat Gan Israel
R.	Avtalion	c/o Bar Ilan University 52900, Ramat Gan Isra Israel
	Okun	c/o Bar Ilan University 52900, Ramat Gan Israel

Number 2 of 2

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

METHOD OF TREATING FISH AND CRUSTACEANS WITH A TELLURIUM BASED IMMUNOMODULATOR

BACKGROUND

5 Fish hold many aspects of the immune system similar to
those of higher vertebrates. Until now, a number of
cytokines have been identified in biological assays on the
basis of their functional similarity to mammalian cytokine
activities or detected through their biological and/or
10 antigenic cross-reactivity with mammalian cytokines (1).
Recently, using computer-based tools, an IL-10 homologue
was characterized in the puffer fish, (*fugu rubripes*) and
predicted to have 183 amino acids (2). We recently
characterized the IL-10 cytokine homologue in tilapia and
15 carp using anti human mAb. SDS-PAGE results showed that IL-
10L MW in both tilapia and carp is about 15 kDa. Such
homology indicates that perhaps it also plays a major role
in the fish immune system. AS101 (ammonium trichloro
[dioxethylene-O, O'] telurate) is a low molecular weight,
20 non toxic compound that has been shown to have immune
regulatory properties (3). Most of its activities have been
primarily attributed to the direct inhibition of the anti-
inflammatory cytokine IL-10, followed by the simultaneous
increase of other cytokines, such as IL-1 α , TNF α , IFN γ , IL-
25 2, IL-12, and GM-CSF (3-6). We examined the effect of AS101
on intracellular levels of tilapia IL-10L in vitro and
showed its ability to decrease intracellular IL-10L
synthesis in a dose dependent manner. Stress response
facilitates IL-10 production and secretion (7), which can
30 cause immune suppression (8). In this study we showed that
IL-10L secretion in vivo is up-regulated during stress
reaction in fish, and that AS101 is able to decrease that
secretion, without affecting the normal stress reaction as
indicated by elevated serum glucose levels. Moreover, a
35 protective effect of AS101 on stressed goldfish (*Carassius
auratus*) infected with the opportunistic pathogen *Aeromonas
salmonicida* was found. Interleukin-10 (IL-10) is known in

mammalians to down-regulate the cellular immunity, resulting in increased susceptibility to opportunistic disease. The ability of the immunomodulator AS101 to down-regulate IL-10 levels has been shown in murines and humans.

5 We have discovered an IL-10-like (IL-10L) cytokine in Tilapia and Carp fish using Western-Blot analysis with human IL-10 mAb and ELISA, and showed IL-10L kinetic expression of LPS stimulated cultures. We have also discovered that air-exposure stress resulted in the in vivo
10 increase of serum IL-10L levels with the increase of blood glucose.

SUMMARY OF THE INVENTION

15 Treatment of fish and crustaceans and in particular stressed fish by exposure to organic based tellurium compounds such as AS101 causes significant inhibition of IL-10L secretion to the serum, without affecting the normal stress reaction of the fish as expressed in increased
20 glucose levels. Moreover stress induced Goldfish that were infected with *Aeromonas salmonicida* bacteria and treated with AS101 had significantly less wounds and mortality than control fish. Accordingly, the invention is directed to the direct or adjunct treatment of bacterial or fungal
25 infections in fish and crustaceans including shell fish. The terms fish and crustaceans are used to include all species of fresh water and salt water fish including fish that are raised in fish farm environments or tropical pet fish as well as lobsters, crayfish, clams, oysters, shrimp,
30 muscles and the like. The invention contemplates providing in the aqueous environment of the fish or crustaceans an amount of an organic tellurium compound that inhibits or treats an infection in fish or crustaceans. These amounts may vary but generally from 0.01 to 10 micrograms of the
35 tellurium compound per ml of water may be employed. The invention also contemplates the concomitant administration of antibiotics, antifungal drugs in conventional doses


along with an organic tellurium compound.

BRIEF DESCRIPTION OF THE DRAWING


- 5 Fig 1. discloses a dose-dependent inhibition of IL-10L by the immunomodulator AS101.
Fig 2. discloses Serum IL-10L levels as measured prior to stress induction and at different intervals of time following stress induction
10 Fig 3. discloses stress induction up-regulates IL-10L and glucose secretion, however, +only IL-10L is inhibited when stressed fish are treated with AS101.
Fig 4. discloses AS101 treated fish infected with *Aeromonas salmonicida* show significantly less wounds ($p=0.073$) than
15 untreated infected fish.
Fig 5. discloses AS101 treated stressed fish infected with *Aeromonas salmonicida* show higher survival rates than control fish.

20 DETAILED DESCRIPTION OF THE INVENTION

The organic tellurium compounds for use in the invention include those of the formula:



40 or



or
 TeO₂ or complexes of TeO₂

(C)

or

20 PhTeCl₃ (D)

or

TeX₄, when X is Cl, Br or F

or

25 (C₆H₅)₄P⁺(TeCl₃(O₂C₂H₄))⁻ (E)


wherein t is 1 or 0; u is 1 or 0; v is 1 or 0; R, R₁, R₂, R₃, R₄, R₅, R₆, R₇, R₈, and R₉ are the same or different and are independently selected from the group consisting of hydrogen, hydroxyalkyl of 1 to 5 carbons, hydroxy, alkyl or

30 from 1 to 5 carbon atoms, halogen, haloalkyl of 1 to 5 carbon atoms, carboxy, alkylcarbonylalkyl of 2 to 10 carbons, alkanoyloxy of 1 to 5 carbon atoms, carboxyalkyl of 1 to 5 carbons atoms, acyl, amido, cyano, amidoalkyl of 1 to 5 carbons, N-monoalkylamidoalkyl of 2 to 10 carbons,


35 N,N-dialkylamidoalkyl of 4 to 10 carbons, cyanoalkyl of 1 to 5 carbons alkoxy of 1 to 5 carbon atoms, alkoxyalkyl of 2 to 10 carbon atoms and -COR₁₀ wherein R₁₀ is alkyl of 1 to 5 carbons; and X is halogen; while the ammonium salt is illustrated, it is understood that other pharmaceutically

40 acceptable salts such as K⁺ are within the scope of the invention. The compounds with the five membered rings are preferred.

As used herein and in the appended claims, the term alkyl of 1 to 5 carbon atoms includes straight and branched chain alkyl groups such as methyl; ethyl; n-propyl; n-butyl, and the like; the term hydroxyalkyl of 1 to 5 carbon atoms includes hydroxymethyl; hydroxyethyl; hydroxy-n-butyl; the term haloalkyl of 1 to 5 carbon atoms includes chloromethyl; 2-iodoethyl; 4-bromo-n-butyl; iodoethyl; 4-bromo-n-pentyl and the like; the term alkanoyloxy of 1 to 5 carbon atoms includes acetyl, propionyl, butanoyl and the like; the term carboxyalkyl includes carboxymethyl, carboxyethyl, ethylenecarboxy and the like; the term alkylcarbonylalkyl includes methanoylmethyl, ethanoylethyl and the like; the term amidoalkyl includes $-\text{CH}_2\text{CONH}_2$; $-\text{CH}_2\text{CH}_2\text{CONH}_2$; $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CONH}_2$ and the like; the term cyanoalkyl includes $-\text{CH}_2\text{CN}$; $-\text{CH}_2\text{CH}_2\text{CN}$; $-\text{CH}_2\text{CH}_2\text{CH}_2\text{CN}$ and the like; the alkoxy, of 1 to 5 carbon atoms includes methoxy, ethoxy, n-propoxy, n-pentoxy and the like; the terms halo and halogen are used to signify chloro, bromo, iodo and fluoro; the term acyl includes R_{16}CO wherein R_{16} is H or alkyl of 1 to 5 carbons such as methanoyl, ethanoyl and the like; the term aryl includes phenyl, alkylphenyl and naphthyl; the term N-monoalkylamidoalkyl includes $-\text{CH}_2\text{CH}_2\text{CONHCH}_3$, $-\text{CH}_2\text{CONHCH}_2\text{CH}_3$; the term N,N-dialkylamidoalkyl includes $-\text{CH}_2\text{CON}(\text{CH}_3)_2$; $\text{CH}_2\text{CH}_2\text{CON}(\text{CH}_2\text{-CH}_3)_2$. The tellurium based compounds that are preferred include those of the formula:




and




wherein X is halogen. The preferred halogen species is chloro.

Other compounds which are based on tellurium and may be used in the practice of the invention include PhTeCl_3 , TeO_2 and TeX_4 (C_6H_5)₄, $\text{P}+(\text{TeCl}_3(\text{O}_2\text{C}_2\text{H}_4))$ - (Z. Naturforsch, 36, 307-312 (1981). Compounds of the following structure are also included:



Other compounds useful for the practice of invention include:



wherein R_{11} , R_{12} , R_{13} and R_{14} are independently selected from the group consisting of hydrogen, hydroxy-alkyl of 1-5 carbons atoms, hydroxy and alkyl of 1-5 carbons atoms.

Useful dihydroxy compounds for use in the preparation of compounds of structure A or B, include those of formula I wherein R, R₁, R₄ and R₅ are as shown in the Table:

TABLE

5	$ \begin{array}{c} \text{R} \quad \text{R}_4 \\ \quad \\ \text{HO} - \text{C} - \text{C} - \text{OH} \\ \quad \\ \text{R}_1 \quad \text{R}_5 \end{array} $				(I)
10	R	R ₁	R ₄	R ₅	
15	H	H	H	H	
	H	Cl	H	H	
	H	OCH ₃	H	H	
	H	COOCH ₃	H	H	
	H	H	CN	H	
20	H	CHO	H	H	
	H	H	COOH	H	
	H	CH ₂ COOH	H	H	
	H	H	CH ₂ COOCH ₃	H	
	H	I	H	H	
25	H	H	Br	H	
	H	H	CONH ₂	H	
	H	H	CH ₂ OH	H	
	H	COOH	H	H	
30					

Other dihydroxy compounds for use in the preparation of compounds A and B include those of formula II wherein R, R₁, R₂, R₃, R₄ and R₅ are as shown in the Table:

(II)

$$\begin{array}{c}
 R \quad R_2 \quad R_4 \\
 | \quad | \quad | \\
 HO - C - C - C - OH \\
 | \quad | \quad | \\
 R_1 \quad R_3 \quad R_5
 \end{array}$$

	R	R ₁	R ₂	R ₃	R ₄	R ₅
15	H	H	H	H	H	H
	H	H	Cl	H	H	H
	H	CH ₂ OH	H	H	H	H
	H	H	OH	H	H	H
	H	H	H	CH ₃	H	H
20	H	H	H	CH ₂ Cl	H	H
	H	H	H	COOH	H	H
	H	H	H	CH ₂ COOH	H	H
	H	H	H	CHO	H	H
	H	H	H	H	H	CH ₂ CHO
25	H	H	CONH ₂	H	H ₂	CH ₃
	H	H	H	CN	H	H
	H	H	H	H	CH ₂ COHN ₂	H
	H	H	H	COOCH ₃	H ₃	H
	H	H ₃	OCH ₃	H	H	H
30						

Other dihydroxy compounds for use in making compound of formula A and B include those of formula III wherein R, R₁, R₂, R₃, R₄ and R₅ are as shown in the Table.

(III)

5

$$\begin{array}{ccccccc}
 & R & R_2 & R_4 & R_8 & & \\
 & | & | & | & | & & \\
 HO - & C - & C - & C - & C - & OH & \\
 & | & | & | & | & & \\
 & R_1 & R_3 & R_5 & R_9 & &
 \end{array}$$

10

R	R ₁	R ₂	R ₃	R ₄	R ₅	R ₈	R ₉
---	----------------	----------------	----------------	----------------	----------------	----------------	----------------

15

H	H	H	H	H	H	H	H
H	H	Cl	H	H	H	H	H
H	H	H	H	Br	H	H	H
H	H	OCH ₃	H	H	H	H	H
H	H	CONH ₂	H	H	H	H	H
H	Br	H	H	H	H	H	H
H	H	H	H	CH ₂ COOH	H	H	H
H	H	Cl	Cl	H	H	H	H
H	CH ₂ COOH	H	H	H	H	H	H
H	H	CH ₃	H	H	H	H	H
H	CH ₃	H	H	H	H	H	H

20


25

H	CH ₂ Cl	H	H	H	H	H	H
H	H	H	I	H	H	H	H
H	CH ₂ CN	H	H	H	H	H	H
H	H	H	H	CH ₂ CH ₂ OH	H	H	H

Additional dihydroxy compounds include those of formula IV wherein R, R₁, R₂, R₃, R₄ and R₅ are as shown in the Table.

5										
	(IV)									
	$ \begin{array}{ccccccccc} & & & R & R_2 & R_4 & R_6 & R_8 & & \\ & & & & & & & & & \\ HO & - & C & - & C & - & C & - & C & - & R & - & OH \\ & & & & & & & & & & & & \\ & & R & & R_3 & & R_5 & & R_7 & & R_9 & & \end{array} $									
10	R	R ₁	R ₂	R ₃	R ₄	R ₅	R ₆	R ₇	R ₈	R ₉
15										
	H	H	H	H	H	H	H	H	H	H
	H	H	Cl	H	H	H	Cl	H	H	H
	H	H	Cl	Cl	H	H	H	H	H	H
20	H	H	CONCH ₃	H	H	H	Br	H	H	H
	H	H	Br	H	H	CON(CH ₃) ₂	H	H	H	H
	H	H	H	OCH ₃	H	H	H	H	H	H
	H	H	H	H	OCH ₃	H	H	H	H	H
	H	H	H	H	CH ₂ COOH	H	H	H	H	H
25	H	H	COOH	H	H	H	H	H	H	H
	H	CH ₃	H	H	H	H	H	H	H	H
	CH ₃	H	H	H	CH ₃	H	H	H	H	H
	H	CH ₂ CH ₃	H	H	H	H	Cl	H	H	H
	H	CH ₂ CN	H	H	CH ₂ OH	H	H	H	H	H
30	H	H	H	I	H	H	H	CN	H	H
	H	CH ₂ CH ₂ COOH	H	H	H	H	H	H	H	H
	H	H	CHO	H	H	H	H	H	H	H
	H	H	H	F	H	H	H	H	H	H

Compounds of the following formula are also included:



5
10 herein R_{15} , R_{16} , R_{17} and R_{18} are independently selected from halogen, alkyl of 1-5 carbons; aryl, acyl of 1-5 carbon hydroxyalkyl of 1-5 carbons and aminoalkyl of 1-5 carbons may be made by reacting the appropriate di, tri or tetrahalotelluride with the appropriate hydroxy compound which may be of the formula: $HO-R_{19}$;

15 wherein R_{19} is alkyl of 1 to 5 carbons, haloalkyl of 1 to 5 carbons, aryl, alkylaryl, alkylamido of 1 to 5 carbons, alkylcarbonyl of 1 to 5 carbons, cyanoalkyl of 1 to 5 carbons, cyanoalkyl of 1 to 5 carbons, and an alkoxyalkyl of 2 to 10 carbons. Specific examples of R_{16} include methyl, ethyl, n-propyl, phenyl, tolyl, amidoethyl, cyanomethyl, methyloxymethyl and CH_2CH_2COOH .

20 These compounds are described in United States Letters Patent No. 4,761,490 which is incorporated by reference. In addition, $TeCl_4$, $TeBr_4$ and compounds which give in aqueous solution TeO_2 preferably in the form of a complex such as for example TeO_2 complex with citric acid or ethylene glycol.

25 The preferred compound is ammonium trichloro (dioxoethylene-O,O') tellurate.

Treatment of Fish

30 Tilapia hybrids (*Oreochromis niloticus* X *O. aureus*) of 100-200 g in weight were raised in the Fish Immunology & Genetics Laboratory, Bar Ilan University. Carp (*Cyprinus carpio*) of 200-350 gr were purchased from the "Mevo-Hamah" farm (Israel). The fish were kept in 400 L plastic tanks with re-circulating water system. Temperature and
35 oxygen levels were kept constant at $26 \pm 2^\circ C$ and 4-6 ppm, respectively. The term "organic tellurium" is defined to mean any tellurium element bonded to an organic moiety, including via atoms that differ from carbon, such as

oxygen.

For in-vitro studies, AS101 was supplied as PBS solution, pH 7.4, at 4°C. For in-vivo experiments, AS101 powder was dissolved in the appropriate concentration in re-circulating water.

Cell Culture

PBL (peripheral blood leukocytes) were isolated from heparinized blood on a ficoll paque bed (Amersham Bioscience) and cultured as previously reported (9). For AS101 treatments, AS101 was added directly to the cultures at final concentration of 0.05 to 0.5 µg/ml.

Fish were subjected to air exposure stress every 60 min for 90 sec during 4 hours (10). The fish were then divided into groups of 3, each separately held in 40L plastic containers at 28°±2°C

Western blot analysis

PBL were lysed as previously reported (6). Samples were electrophoresed on 12% SDS-PAGE and blotted with anti-human-IL-10 mAb (Santa Cruz Biotechnology, Inc sc-8438) (1:660 dilution) and HRP-conjugate secondary Ab (Jackson Immuno-Research) (1:6600 dilution).

Serum IL-10L detection

Fish blood was coagulated during 2 hours at room temperature, then centrifuged for 10 min at 1800 x g. IL-10L levels were quantified in the collected sera using ELISA (Human Interleukin-10 ELISA Kit, pierce-endogen) according to manufacturer's instructions.

Stress intensity control

Blood samples were taken 1 hour after stress induction, sera separated by centrifugation as above and glucose levels were measured using Glucose TRINDER reagent (Sigma) according to manufacturers instructions, in a 96 microwell plate at 490 nm.

Results

AS101 effect on the intracellular IL-10L levels of tilapia cell cultures

AS101 caused significant inhibition of intracellular tilapia IL-10L synthesis. This inhibitory effect was dose-dependant and complete inhibition was achieved with 0.5 µg/ml AS101 (Fig. 1).

5 Influence of extensive stress on serum IL-10L levels

Serum IL-10L levels were measured prior to stress induction and at different intervals of time (1, 5, 6, 8, 16, 20, and 24 Hrs) following stress induction. Significant IL-10L increase ($p=0.001$) started at 1 hour post stress, peaked on hours 8-16 and underwent significant decrease ($p=0.006$) afterwards (Fig. 2). AS101 effect on stress induced serum IL-10L and glucose levels

15 The maximal AS101 effect on IL-10L level (decrease from 719 to 209 pg/ml) was obtained 2 hours post-stressed following bath immersion in a 20-ppm water solution of this compound. AS101 treatment, while affecting IL-10L, had no effect on blood glucose levels which remained high ($190 \text{ mg/dl} \pm 0.12$) as in control stressed fish, (Fig. 3)

20 AS101 effect on stressed fish infected with *Aeromonas salmonicida*

Stress induced fish that were immersed in soluble AS101 after being exposed to *Aeromonas salmonicida* had significantly lower number of wounds per fish (fig.4) and higher rate of survival (fig.5) in contrast to stressed fish infected with the bacteria and not treated with AS101. AS101 inhibits tilapia intracellular IL-10L in vitro in a dose dependant manner. The possibility that the inhibition was due to cell toxicity, was examined Blue staining, and did not show elevated cell death beyond control in all AS101 doses, indicating that AS101 has no which were taken 6 hours after stress induction and bath immersion in different AS101 concentrations showed a significant IL-10L decrease, mainly with AS101 dose of 20 µg/ml which was the most efficient. These results show that AS101 reached the fish blood probably

by penetrating through the skin, the gills or the gut epithelia. Interestingly, both IL-10L and glucose, which showed significant blood elevation following stress induction, only IL-10L, was down regulated by the AS101 treatment.

These results suggest that the protective role of AS101 against *Aeromonas salmonicida* infections in stressed goldfish involves AS101 mediated IL-10L inhibition, emphasizing it as an effective agent against stress-induced immune suppression.

References which are incorporated into this application:

[1] Takashi Y, Teruyuki N. Interaction between the endocrine and immune Systems in Fish. *Int Rev Cytol.* 220:35-92 ; 2002

[2] Jun Z, Melody SC, Secombes CJ. Characterisation, expression and promoter analysis of an interleukin 10 homologue in the pufferfish (*Fugu rubripes*). 55(5): 325-35 ; Aug 2003

[3] Sredni B, Caspi RR, Klein A, Kalechman Y, Danziger Y, Ben Ya'akov, M Tamari T, Shalit F, Albeck M.. A new immunomodulating compound (AS-101) with potential therapeutic application. *Nature.* 330(6144) : 173-176 ; Nov 1987

[4] Strassmann G, Kambayashi T, Jacob CO, Sredni B. The immunomodulator AS-101 inhibits IL-10 release and augments TNF alpha and IL-1 alpha release by mouse and human mononuclear phagocytes. *Cell. Immunol.* 176: 180 ; 1997.

[5] Kalechman Y, Zuloff A, Albeck M, Strassmann G, Sredni B. Role of endogenous cytokines secretion in radioprotection conferred by the immunomodulator ammonium trichloro (dioxymethylene-0-0') tellurate *Blood.* 85: 1555 ; 1995

[6] Kalechman Y, Longo DL, Catane R, Shani A, Albeck M, Sredni B. Synergistic anti-tumoral effect of paclitaxel (Taxol)+AS101 in a murine model of B16 melanoma: association with ras-dependent signal-transduction

pathways Int. J. cancer. 86: 281; 2000

[7] Elenkov IJ and Chrousos GP. Stress Hormones, Proinflammatory and antiinflammatory Cytokines, and Autoimmunity. Ann. N. Y. Acad Sci. 966: 290-303; 2002

5 [8] Akdis CA, Blaser K. Mechanisms of interleukin-10-mediated immunesuppression. 103 (2): 131 -6 ;Jun 2001

[9] Rosenberg-Wiser S. and Avtalion RR. The cells involved in the immune response of fish. III. Culture requirement for phytohemagglutinin stimulated peripheral
10 carp lymphocytes. Devel. Comp. Immunol. 6:693-702 ; 1982

[10] Melamed O, Timan B, Avtalion RR and Noga EJ. Design of a stress model in the hybrid bass (Morone saxatilis x Morone Chrysops). Isr. J. Aquac-Bamidqeh. 51(1): 10-16 ; 1999

15 Claim:

A method for the direct or adjunct treatment of bacterial or fungal infections in fish and crustaceans including shell fish which comprises providing an effective amount of an organic tellurium in an aqueous environment to
20 which said fish or crustaceans are exposed.




Fig 1




Fig 2




Fig 3




Fig 4




Fig 5

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.